These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38293784)

  • 1. Bulk and single-cell transcriptome reveal the immuno-prognostic subtypes and tumour microenvironment heterogeneity in HCC.
    Ji D; Lu S; Zhang H; Li Z; Wang S; Miao T; Jiang Z; Ao L
    Liver Int; 2024 Apr; 44(4):979-995. PubMed ID: 38293784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data.
    Qu Y; Gong X; Zhao Z; Zhang Z; Zhang Q; Huang Y; Xie Q; Liu Y; Wei J; Du H
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value and potential mechanism of cellular senescence and tumor microenvironment in hepatocellular carcinoma: Insights from bulk transcriptomics and single-cell sequencing analysis.
    Qu C; Wu Q; Lu J; Li F
    Environ Toxicol; 2024 May; 39(5):2512-2527. PubMed ID: 38189188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of TME and Identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma.
    Liu L; Zhang R; Deng J; Dai X; Zhu X; Fu Q; Zhang H; Tong Z; Zhao P; Fang W; Zheng Y; Bao X
    Cancer Immunol Immunother; 2022 Jan; 71(1):121-136. PubMed ID: 34028567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning-based integration develops a neutrophil-derived signature for improving outcomes in hepatocellular carcinoma.
    Gong Q; Chen X; Liu F; Cao Y
    Front Immunol; 2023; 14():1216585. PubMed ID: 37575244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis
    Chi H; Zhao S; Yang J; Gao X; Peng G; Zhang J; Xie X; Song G; Xu K; Xia Z; Chen S; Zhao J
    Front Immunol; 2023; 14():1137025. PubMed ID: 37006257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of single-cell RNA sequencing and bulk RNA transcriptome sequencing reveals a heterogeneous immune landscape and pivotal cell subpopulations associated with colorectal cancer prognosis.
    Zhang Q; Liu Y; Wang X; Zhang C; Hou M; Liu Y
    Front Immunol; 2023; 14():1184167. PubMed ID: 37675100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
    J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment.
    Wang J; Lou J; Fu L; Jin Q
    J Int Med Res; 2021 Feb; 49(2):300060520980646. PubMed ID: 33567957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
    Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
    BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 18. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
    Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
    Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
    Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
    Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
    Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
    Front Immunol; 2022; 13():994019. PubMed ID: 36177006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.